Shelter Pharma Bags Overseas Veterinary Order; Shares Locked at Upper Circuit

Mumbai, July 10: Shelter Pharma Ltd. spent Friday in the spotlight after announcing an export order for its veterinary products, prompting the stock to hit its upper circuit despite the relatively modest size of the contract.

The Ahmedabad-based company said it has received a purchase order from Al-Saqr Agro for Agricultural and Veterinary Entries, an international customer, for the supply of animal healthcare products valued at US$27,664.

The order covers Multia Liquid in different pack sizes and Super Vitamas, products used as veterinary nutritional supplements. According to the exchange filing, the buyer will make 100% advance payment, while deliveries will be executed under mutually agreed shipment schedules.

On paper, the contract is not a large revenue contributor. But for a company of Shelter Pharma’s scale, every overseas customer adds another reference point in export markets, where repeat business often matters more than the value of the first shipment.

Small Order, Bigger Signal

Investors appeared to look beyond the headline value.

The company itself described the order as another step in strengthening its international presence, adding that overseas demand is expected to support future business expansion.

The filing also stated that the transaction was received in the ordinary course of business, with no promoter or group company interest in the customer. The deal is not a related-party transaction.

Stick Market Snapshot

The market reacted swiftly after the disclosure.

Shelter Pharma share price climbed to ₹27.40, locking at the day’s upper circuit as of 3:49 PM IST on July 10.

For a stock where liquidity is often limited, even relatively small corporate developments can trigger sharp price moves if investors believe they improve the company’s long-term business outlook. 

Company Background

Shelter Pharma develops and manufactures herbal healthcare and veterinary products, with animal nutrition forming an important part of its portfolio. Alongside its domestic business, the company has been gradually building an export presence through overseas distributors and institutional buyers.

The latest order is unlikely to transform earnings on its own. What it does offer is another indication that Shelter Pharma is finding customers outside India, an area investors in smaller healthcare companies tend to watch closely because sustained export traction can gradually reduce dependence on the domestic market.

Source:

• https://www.bseindia.com/stock-share-price/shelter-pharma-ltd/shelter/543963
• https://www.bseindia.com/xml-data/corpfiling/AttachLive/b78ef024-49d4-4f53-9905-e69c25050469.pdf